NACI chair explains decision to wait before reversing course on AstraZeneca vaccine

Chair of the National Advisory Committee on Immunization (NACI) Dr. Caroline Quach explained Tuesday the lag in its decision to reverse course on the Oxford-AstraZeneca vaccine and offer it to seniors aged 65 and over, saying they had been waiting on a randomized control trial out of the U.S. She said when the results of the trial were delayed until April, they decided to move ahead with “real world evidence.”